[2] Fang W, Zhao S, Liang Y, et al. Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma. Oncologist. 2020 Mar;25(3):e545-e554. doi: 10.1634/theoncologist.2019-0547. [3] ...
5、Pillai RN, Behera M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017;123(21):4099-4105. 6、Offin M, Feldman D, Ni A, et al. Frequency and outcomes o...
[1]Pillai RN, et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017;123:4099-105. [3]Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer[J]. N Engl J Med. 2022 Jan 20;386(3)...
et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017; 123:4099-105. 6. Offin M, et al. Frequency and Outcomes of Brain Metastases in Patients With HER2-Mutant Lung Cancers. Cancer. 2019;...
13. Pillai RN, et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017;123:4099-105. 14. Offin M, et al. Frequency and Outcomes of Brain Metastases in Patients With HER2-Mutant Lung Cancers. Cancer. 2019;125:4380-7. 15. Zhou J,...
13. Pillai RN, et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017;123:4099-105. 14. Offin M, et al. Frequency and Outcomes of Brain Metastases in Patients With HER2-Mutant Lung Cancers. Cancer. 2019;125:4380-7. ...
DESTINY-Lung01为一项开放标签、多中心、多队列的II期临床研究,在不可切除和/或转移性非鳞NSCLC患者的2个队列——HER2过表达(免疫组化2+或3+)队列和HER2突变NSCLC队列中评估DS-8201的疗效。主要终点为ICR(独立中央审查委员会)评估的ORR(客观缓解率;CR+PR)。
[10].Kumagai S, Koyama S, Nishikawa H. Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 2021;21(3):181-197. doi:10.1038/s41568-020-00322-0 [11].Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphoryla...
正是在这样的背景下,为了深入了解 LUAD 伴有 HER2 突变患者的临床特征和 CT 纹理特征,来自复旦大学附属华东医院的研究人员开展了这项研究,并将研究成果发表在了《BMC Cancer》期刊上,论文题目是《Clinical characteristics and computed tomography texture features of lung adenocarcinoma patients with HER2 mutation》...
[4]. Pillai R, et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017;1;123(21): 4099-4105. .[6]. Siena S, et al. Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) Oncogene in Colorectal Cancer. Ann Oncol. 2018 May...